Business|Health
GSK buys COVID, influenza vaccines from retrenching CureVac
British drugmaker GSK on Wednesday bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials and extending the
July 03, 2024